JP2025026846A5 - - Google Patents

Info

Publication number
JP2025026846A5
JP2025026846A5 JP2024187067A JP2024187067A JP2025026846A5 JP 2025026846 A5 JP2025026846 A5 JP 2025026846A5 JP 2024187067 A JP2024187067 A JP 2024187067A JP 2024187067 A JP2024187067 A JP 2024187067A JP 2025026846 A5 JP2025026846 A5 JP 2025026846A5
Authority
JP
Japan
Prior art keywords
tumor
pharmaceutical composition
inhibitor
mcc
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024187067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025026846A (ja
Filing date
Publication date
Priority claimed from JP2021522967A external-priority patent/JP7653907B2/ja
Application filed filed Critical
Publication of JP2025026846A publication Critical patent/JP2025026846A/ja
Publication of JP2025026846A5 publication Critical patent/JP2025026846A5/ja
Pending legal-status Critical Current

Links

JP2024187067A 2018-10-30 2024-10-24 p53WT腫瘍の処置の方法 Pending JP2025026846A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862752382P 2018-10-30 2018-10-30
US62/752,382 2018-10-30
JP2021522967A JP7653907B2 (ja) 2018-10-30 2019-10-28 p53WT腫瘍の処置の方法
PCT/US2019/058319 WO2020092221A1 (en) 2018-10-30 2019-10-28 Method of treatment of p53 wt tumors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021522967A Division JP7653907B2 (ja) 2018-10-30 2019-10-28 p53WT腫瘍の処置の方法

Publications (2)

Publication Number Publication Date
JP2025026846A JP2025026846A (ja) 2025-02-26
JP2025026846A5 true JP2025026846A5 (cg-RX-API-DMAC7.html) 2025-10-10

Family

ID=68582462

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021522967A Active JP7653907B2 (ja) 2018-10-30 2019-10-28 p53WT腫瘍の処置の方法
JP2024187067A Pending JP2025026846A (ja) 2018-10-30 2024-10-24 p53WT腫瘍の処置の方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021522967A Active JP7653907B2 (ja) 2018-10-30 2019-10-28 p53WT腫瘍の処置の方法

Country Status (10)

Country Link
US (1) US12115151B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873460B1 (cg-RX-API-DMAC7.html)
JP (2) JP7653907B2 (cg-RX-API-DMAC7.html)
KR (1) KR102879859B1 (cg-RX-API-DMAC7.html)
CN (1) CN112996503A (cg-RX-API-DMAC7.html)
AU (1) AU2019369216B2 (cg-RX-API-DMAC7.html)
CA (1) CA3115716A1 (cg-RX-API-DMAC7.html)
ES (1) ES2986421T3 (cg-RX-API-DMAC7.html)
IL (1) IL282485B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020092221A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
CN115216514B (zh) * 2022-08-01 2026-03-17 中国科学技术大学 Vam6(Vps39)作为靶点在药物筛选、基因编辑以及疾病治疗中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3541387T3 (pl) * 2016-11-15 2021-10-25 Novartis Ag Dawka i schemat dla inhibitorów interakcji hdm2-p53

Similar Documents

Publication Publication Date Title
Yun et al. Repotrectinib exhibits potent antitumor activity in treatment-naïve and solvent-front–mutant ROS1-rearranged non–small cell lung cancer
Daver et al. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
Qian et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
JP2021098740A5 (cg-RX-API-DMAC7.html)
Miller et al. MEK1/2 inhibitors in the treatment of gynecologic malignancies
JP2018535951A5 (cg-RX-API-DMAC7.html)
Bouwman et al. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
Osby et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial
Shtivelman et al. Molecular pathways and therapeutic targets in lung cancer
Patyna et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity
Johnson et al. Update on the targeted therapy of melanoma
JP2019216716A5 (cg-RX-API-DMAC7.html)
Bailón-Moscoso et al. Development of anticancer drugs based on the hallmarks of tumor cells
JP2019142930A5 (cg-RX-API-DMAC7.html)
JP2019513694A5 (cg-RX-API-DMAC7.html)
JP2019507721A5 (cg-RX-API-DMAC7.html)
RU2020114632A (ru) Терапевтические способы, относящиеся к ингибиторам hsp90
Kircher et al. Targeting angiogenesis in colorectal cancer: tyrosine kinase inhibitors
Penel et al. O-Mel-Inib: a Cancero-pole Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma
Desai et al. Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options
Fishman et al. Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma
Altan et al. Management of small cell lung cancer: progress and updates
Dabney et al. Molecular pathways and targeted therapy in cholangiocarcinoma
Sanborn et al. A randomized, double‐blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive‐stage small cell lung cancer: Hoosier Cancer Research Network LUN06‐113
JP2009538318A5 (cg-RX-API-DMAC7.html)